HNB
GTBP icon

Hilltop National Bank’s GT Biopharma GTBP Stock Holding History

Hilltop National Bank’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49 Hold
100
– – ﹤0.01% 804
2026
Q1 		$41 Buy
+100
New +$55 ﹤0.01% 794

Other funds holding GTBP

EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
TWP
Tempus Wealth Planning Irvine, California $511M AUM 28.39% 1-Year Est. Return
AIS
AM Investment Strategies Chattanooga, Tennessee $521M AUM 33.22% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Hilltop National Bank's GTBP Position: Q2 2026 in Review

Hilltop National Bank held its GT Biopharma (GTBP) position steady in Q2 2026 at 100 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #804.

Hilltop National Bank first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Hilltop National Bank held 100 shares of GT Biopharma worth $49 as of Q2 2026.
  • Hilltop National Bank left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Hilltop National Bank's portfolio in Q2 2026, its #804 holding.
  • Hilltop National Bank first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Hilltop National Bank's 13F filing for Q2 2026, filed 2 Jul 2026.